Phase II study with @entity1311 for the treatment of advanced inoperable XXXX .

@entity1 @entity137 @entity390 @entity5344 @entity5 @entity1149 @entity1311 @entity305 @entity391 @entity1398 @entity4841 @entity925
@entity1311 is a plant product isolated from the bark of the Western yew (Taxus brevifolia) that promotes the formation and stabilization of microtubules. This leads to growth arrest in the G2/M phase of the cell cycle. @entity1311 has demonstrated significant antineoplastic activity in different @entity5 types, most notably in @entity5344 . In two Phase II trials (Eastern Cooperative Oncology Group [ECOG]/M.D. Anderson) in @entity1 with previously untreated Stage IIIB-IV @entity1149 ( @entity1149 ), response rates of 21% and 24% were reported. We are performing a Phase II trial investigating the efficacy of @entity1311 in @entity1 with inoperable Stage IIIB-IV @entity1149 . Forty-three @entity1 were treated, 31 males and 12 females, with a median age of 59 years (range, 29-75), ECOG performance status 0-2, Stage IIIB 30%, Stage IV 70%. @entity1 were treated every 3 weeks with 225 mg/m2 as a 3-h infusion with standard premedication. Preliminary efficacy results from 37 @entity1 include partial remissions in eight (21.6%) @entity1 , no change in 22 (59.5%) and disease progression in seven (19%) @entity1 . Eight @entity1 are still receiving therapy. The hematologic @entity137 (n = 43) were mild, and no World Health Organization (WHO) Grade 4 @entity1398 was observed. Nonhematologic @entity137 were Grade 1/2 @entity305 in 97.6%, Grade 1-3 @entity925 / @entity4841 in 76%, and Grade 1-3 @entity390 / @entity391 in 18.6% of the @entity1 . In conclusion, @entity1311 is an active single agent in this @entity1 population. Mild hematologic @entity137 were observed in the 3-h infusion setting (compared with 24-h infusion) and therapy was well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)
